ArticlePDF Available

An international survey of sleeping problems in the general population

Authors:
  • Université Paris Descartes - Sorbonne Paris Cité; APHP

Abstract and Figures

This international omnibus survey investigated the prevalence and characteristics of sleep problems, as well as strategies for resolving sleep problems, in the general population of the USA, France, Germany, Italy, Spain, the UK and Japan. Research design and methods: A representative sample of the general population aged > or = 15 years was recruited from each country. Questions focused on the nature of sleeping problems, the impact of problems on daily functioning and behavior with regard to resolving sleeping problems. A total of 10 132 individuals were included in this survey. The prevalence of sleeping problems was 56% in the USA, 31% in Western Europe and 23% in Japan. Most individuals with sleeping problems considered these to have an impact on their daily functioning, with family life most affected in the Western European sample, personal activities in the US sample and professional activities in the Japanese sample. Almost half of individuals with sleep problems had never taken any steps to resolving them, and the majority of respondents had not spoken with a physician about their problems. Of those individuals who had consulted a physician, drug prescriptions had been given to approximately 50% in Western Europe and the USA and 90% in Japan. Sleeping problems continue to present a considerable burden across Western Europe, the USA and Japan. Despite this, they are under-reported and under-treated, with almost half of affected individuals not taking any steps to resolve their sleeping problems.
Content may be subject to copyright.
2008
Paper 3615 307
ABSTRACT
ORIGINAL ARTICLE
An international survey of
sleeping problems in the
general population
D. Léger
a
, B. Poursain
b
, D. Neubauer
c
and
M. Uchiyama
d
a
Centre du Sommeil et de la Vigilance, Hôtel-Dieu de Paris,
Université Paris Descartes, Paris, France
b
TNS Healthcare – International Department, Paris, France
c
Sleep Disorder Center, Johns Hopkins University, Baltimore, MD, USA
d
Department of Neuropsychiatry, Nihon University School of Medicine,
Tokyo, Japan
Address for correspondence: Dr. D. Léger, Centre du Sommeil, Hôtel-Dieu de Paris, APHP,
Université Paris Descartes, 1 Place du Parvis Notre-Dame, 75151 Paris Cedex 04, France.
Tel: +33 1 42 34 82 43; Fax: + 33 1 42 34 82 27; damien.leger@htd.aphp.fr
Key words: Multinational – Prevalence – Sleep disorders – Survey – Treatment
Introduction
Insomnia can be defined as difficulty falling asleep,
difficulty maintaining sleep, early-morning awakening
and non-restorative sleep with associated daytime
consequences
1–4
. However, the wide range of distinctive
etiologies and varying degrees of sleep disturbance often
make classification difficult. Depending on definition
and regions, up to one-third of the population may
exper ience insomnia symptoms
5–13
. For example, on
a large cross-sectional telephone survey conducted in
a representative sample of the populations of France,
the UK, Germany, Italy, Portugal and Spain, difficulty
initiating or maintaining sleep for at least three nights
Objective: This international omnibus survey
investigated the prevalence and characteristics of
sleep problems, as well as strategies for resolving
sleep problems, in the general population of the
USA, France, Germany, Italy, Spain, the UK and
Japan.
Research design and methods: A representative
sample of the general population aged
15 years
was recruited from each country. Questions
focused on the nature of sleeping problems,
the impact of problems on daily functioning
and behavior with regard to resolving sleeping
problems.
Results: A total of 10
132 individuals were
included in this survey. The prevalence of sleeping
problems was 56% in the USA, 31% in Western
Europe and 23% in Japan. Most individuals with
sleeping problems considered these to have an
impact on their daily functioning, with family
life most affected in the Western European
sample, personal activities in the US sample and
professional activities in the Japanese sample.
Almost half of individuals with sleep problems
had never taken any steps to resolving them,
and the majority of respondents had not spoken
with a physician about their problems. Of those
individuals who had consulted a physician, drug
prescriptions had been given to approximately
50% in Western Europe and the USA and 90% in
Japan.
Conclusions: Sleeping problems continue to
present a considerable burden across Western
Europe, the USA and Japan. Despite this, they are
under-reported and under-treated, with almost
half of affected individuals not taking any steps to
resolve their sleeping problems.
CURRENT MEDICAL RESEARCH AND OPINION®
VOL. 24, NO. 1, 2008, 307–317
© 2008 LIBRAPHARM LIMITED
0300-7995
doi:10.1185/030079907X253771
All rights reserved: reproduction in whole or part not permitted
308 Omnibus: sleep problems in the general population © 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1)
per week was reported by 27% of the sample; however,
half of these individuals did not have a diagnosis of a
sleep or mental disorder as defined by the Diagnostic
and Statistical Manual of Mental Disorders 4th
edition (DSM-IV)
7
. While data from Asian populations
are limited, the overall prevalence of insomnia in a
representative sample from the general population of
Japan was 21.4% in the month preceding the survey,
mainly attributed to difficulty maintaining sleep and
falling asleep
12
. Multiple logistic regression analysis
showed that advanced age, being unemployed, lack
of habitual exercise, perceived poor health, and stress
were associated with a higher likelihood of insomnia.
Sleep disturbances have a potentially serious health
impact. An analysis of 28 epidemiological studies found
that insomnia is associated with psychological disorders,
being a risk factor for depression, anxiety disorders, alcohol
and drug abuse, and suicide
14
. This supports the findings
of a number of other studies in various populations
9,15,16
.
Furthermore, there is at the very least an association
between insomnia and decreased immune function
14
,
and a possible association with cardiovascular disease
16
.
Several studies have shown that daytime sleepiness is a
risk factor for motor vehicle accidents
9,17
and may have
considerable socio-professional con sequences, including
increased absenteeism from work
18,19
.
Health-related quality of life (HRQOL) is nearly
always affected in patients experiencing excessive day-
time sleepiness or difficulty initiating or maintaining
sleep, according to the findings of the large Sleep Heart
Health Study
20
. In this study, HRQOL was evaluated with
the generic Short-Form 36 (SF-36) Health Outcomes
Questionnaire in over 5800 individuals in the general
US population. Impairments in HRQOL associated with
subjective sleep symptoms were found to be of a similar
degree to other chronic diseases. Likewise, individuals
self-reporting insomnia for at least three nights a week
over a month had statistically lower scores on all subscales
of the SF-36 compared with individuals without sleep
problems
21
. These findings support those of a French study
showing that, even after excluding patients with DSM-IV
criteria for anxiety or depression, insomnia is associated
with reduced emotional and mental health status
22
. In this
analysis, reductions in SF-36 scores correlated with the
severity of insomnia.
The impact of insomnia on health and HRQOL
translate into economic consequences. Walsh and
Engelhardt estimated the direct costs of insomnia (costs
of substances used to treat the condition and related
healthcare services) in the USA were almost US$14
billion
in 1995, much of which was attributed to nursing home
care for the elderly
23
. In France in 1995, estimates of the
direct costs of insomnia were US$2
billion
24
. It should be
noted that these values do not take into consideration the
indirect or related costs of insomnia such as reduced work
productivity or increased likelihood of accidents, which
would be expected to at least double the economic burden
of sleep disorders
25
. Indeed, a French study comparing
individuals with severe insomnia with good sleepers
matched for professional activities and work schedules
found that those with sleep problems missed twice as
many workdays during the previous year
18
. Furthermore,
individuals with insomnia reported more difficulties with
concentration and an increased frequency of work-related
accidents.
While sleep disturbances clearly contribute to a
significant health and economic burden, evidence
suggests that they are under-reported and under-treated.
In an omnibus consumer survey conducted in France,
Germany, Italy and the UK, it was found that 37% of
respondents with insomnia took no action to resolve
it at all, while 10% used over-the-counter remedies
and 13% adopted non-pharmacological measures
26
. A
recent survey conducted in Western Europe, the USA
and Japan demonstrated that the burden of insomnia
on sufferers is considerable, although only 3% (Japan)
to 22% (France) of individuals consulted a physician
about their symptoms
27
. However, if insomnia and its
consequences on daytime functioning are to be better
understood, there is clearly a lack of understanding on
the strategies used by patients with insomnia to cope
with sleep disorders and daytime impairment.
Based on these preliminary data, we wanted to deepen
our knowledge of insomnia in a more extensive and world-
wide representative sample. The goal of this international
omnibus survey was to further investigate the prevalence
and characteristics of sleep problems, as well as strategies
for resolving them in the general population of the USA,
France, Germany, Italy, Spain, the UK and Japan.
Methods
A representative sample of the general population aged
15 years was recruited from the USA, France, Germany,
Italy, Spain, the UK and Japan in October 2005. Data
were collected by computer-assisted telephone interviews
as part of multi-client monthly omnibus surveys
conducted by LH2 in France, TNS in Germany, TRIBE
in Italy, TNS in Spain and QRS in the UK.*
* TNS (Taylor–Nelson Sofres group), www.tnsglobal.com; TNS Healthcare is a sector of the TNS group, www.tns-healthcare.
com; LH2, previously named Louis Harris France, is a full-service MR company based in Paris, www.LH2.fr; TRIBE special-
izes in medical fieldwork and is based in Milan, no specific website; QRS is a fieldwork company based near London and
specializes in quantitative data collection, www.qrs-research.co.uk; NRC (Nippon Research Center) is a member of Gallup
International Network (GIA), www.nrc.co.jp/english/.
© 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1) Omnibus: sleep problems in the general population Léger et al. 309
In the USA, data were collected via an online
panel facilitated by TNS, and in Japan via a postal
questionnaire facilitated by NRC. These local fieldwork
agencies conducted this study according to international
standards. TNS was selected because it has offices and
a good reputation in poll studies in France, Germany,
Spain, USA and Japan. TNS was not represented in
Italy and the UK but has experience in the field with
the selected companies TRIBE and QRS.
For the telephone interviews, an automated dialing
system was used to randomly select telephone numbers
based on files stratified according to region and city
size. Quotas on age, gender and the employment status
of the head of the family were applied. Recruitment of
participants for the online and postal panels were based
on representative files of national populations. Ethical
rules regarding confidentiality of data were strictly
observed in each country and guaranteed by each local
fieldwork agency. Any third parties did not have access
to respondents’ identities.
A semi-structured omnibus survey, consisting of a
standardized 10–15-minute interview, was conducted
over the telephone by professional interviewers, or
was provided as an online or postal questionnaire
on a weekly or monthly basis. The questions were
identical regardless of whether they were answered
over the telephone, via the internet or on paper and
the questions did not include features that would bias
the responses. Respondents were eligible to complete
the survey if they answered to the following question
in the affirmative: ‘Have you suffered from sleeping
problems in the past 12 months?’ The questionnaire
asked respondents about the nature of their sleeping
problems in terms of symptoms, frequency and
duration. Questions also focused on which sleeping
symptoms caused the greatest degree of concern,
how sleeping problems had evolved over time and the
impact of sleeping problems on daily functioning.
Insomnia was defined as having at least one sleep
problem (difficulty falling asleep, difficulty staying
asleep due to night-time awakenings, waking up early
and not being able to go back to sleep, poor quality of
sleep) experienced at least several times per week for
more than 1 year, with daytime consequences. People
who have been diagnosed with sleep apnea or restless
legs syndrome were excluded.
Behavior regarding resolving sleep problems was
also investigated: respondents were questioned as to
whether they had consulted a physician about their
sleep problems, or whether they had received a drug
prescription for their symptoms. Questions included:
‘have you ever talked about these sleep problems with
a physician?, ‘what type of physician did you consult?’,
did the physician prescribe you a drug for your
sleeping problems?’, ‘did you take the drug prescribed
by the physician?’, and for how long did you take
it?’ The level of satisfaction with treatment for sleep
problems was assessed on a numerical 10-point rating
scale, with 1 representing ‘not satisfied at all’ and 10
indicating ‘very satisfied’. There was no question about
continuous versus intermittent use.
Respondents were also asked whether they found
sleep problems to be troublesome (phrased as
whether they were ‘very bothered’, ‘bothered’, or ‘not
bothered’).
Questionnaires were translated in each country and
care was taken not only with linguistic aspects (checked
by TNS writers) but also with sleep issues (validated
by sleep specialists from each country considered). A
special meeting between specialists at the beginning of
the study was devoted to these issues.
Different channels were used to interview people
depending of the country.
Only face-to-face omnibuses are available in Japan ●
because phone and web interviews are not accepted
by the public.
Web interviews are particularly suitable for the ●
American market because of the large internet
penetration in all age brackets (allowing large size
samples).
Phone interviews were the best solution in Western ●
Europe because of the low penetration rate of the
internet in the elderly population (which is the
population having sleeping disturbances the most
frequently) and a lower cost/effectiveness ratio for
face-to-face methodology in this case.
Categorical values are presented as percentages with
95% confidence intervals (CIs). A chi-squared analysis
of survey results was conducted to assess relationships
between respondent characteristics and the impact
of their sleep problems on daily functioning or the
likelihood of receiving a drug prescription to treat sleep
symptoms as well as to identify country specificities.
Data were extrapolated to the population of
each country (aged
15 years), based on 2005 USA
Census Bureau data (USA: 234
934
412; France:
49
498
357; Germany: 70
586
441; Italy: 50
017
532;
Spain: 34
531
882; the UK: 49
721
174; and Japan:
109
221
888).
A weighting was performed to adjust our sample to the
structure of each population at a national level, in terms
of age, gender and household socioeconomic level.
Results
Population characteristics
The study population was composed of a total of
10
132 individuals (3962 from the USA, 1002 from
310 Omnibus: sleep problems in the general population © 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1)
France, 1001 from Germany, 1000 from Italy, 1002
from Spain, 1000 from the UK and 1165 from Japan),
who were representative of the national population
of their respective countries in terms of region, age,
gender and head of family occupation.
Prevalence of sleeping problems
The overall prevalence of perceptions of sleeping
problems was the greatest in the USA (56%; 95% CI
54–58%). In Western Europe, the prevalence was 34%
in France (95% CI 31–37%), 33% in Germany (95% CI
30–36%), 30% in Italy (95% CI 27–33%), 23% in Spain
(95% CI 20–26%) and 36% (95% CI 33–39%) in the
UK, while the prevalence in Japan was 23% (95% CI
21–25%).
Subjects reporting sleep apnea or restless legs
syndrome were excluded from the study:
6% of the population in Western Europe, 11% in ●
the US, 3% in Japan declared that they suffered
from sleep apnea.
11% of the population in Western Europe, 17% in ●
the US, 2% in Japan declared that they suffered
from restless legs syndrome.
The number of patients with insomnia per se (based on
at least one sleep problem experienced at least several
times per week for more than 1 year, with daytime
consequences) can be evaluated to be 28%, 39% and
21% of the European, US and Japanese respondents,
respectively who reported having sleeping problems
during the previous 12 months (excluding sleep apnea
and restless legs syndrome).
The gender and age characteristics of the total and
sleeping problems groups are shown in Table 1.
The impact of age on the prevalence of insomnia
differed according to region: in Japan, the highest
prevalence of sleeping problems was in those aged
55–64 years (25%), while in Western Europe and the
USA, the highest prevalence was in those in the 35–44
year age group (22% and 20%, respectively).
Types of sleep problem
Of the individuals reporting sleep problems (excluding
sleep apnea or restless legs syndrome), difficulty
maintaining sleep was the most common complaint
in the USA and Western Europe, but problems with
sleep induction was most common in Japan. More
respondents from the USA reported poor sleep quality
than those from other regions (Figure 1). A total of 43%
(95% CI 40–46%), 62% (95% CI 60–64%), and 48%
(95% CI 42–54%) of participants in Western Europe,
the USA and Japan, respectively, reported more than
one sleeping problem, with 17% (95% 15–19%), 26%
(24–28%), and 11% (95% CI 7–15%) of respondents
experiencing difficulty with all aspects: sleep induction,
sleep maintenance and quality of sleep.
In individuals reporting more than one sleep
problem, poor sleep maintenance was most common
in the USA, while difficulty getting to sleep was more
common in Japan. Both problems were reported to a
similar extent by European respondents. Conversely,
poor sleep quality was not as common as the other two
sleep parameters in any region.
Development of sleep problems
In participants with sleep problems, 59% (95% CI
56–62%) of respondents from Western Europe, 52%
(95% CI 50–54%) of those from the USA and 85%
(95% CI 81–89%) from Japan reported that their main
sleep problem had not changed in severity over time. In
participants who did report a change in their main sleep
problem, this was considered to be a deterioration by
46% (95% CI 42–50%) of European respondents, 78%
Table 1. Gender and age characteristics of the total population and of the sleeping problems group
Participants (%)
ASU
(n = 3962)
Western Europe
(n = 5005)
Japan
(n = 1165)
15 % ,redneg elaM (44) 84 (39) )14( 54
% ,egA
)31( 51 )51( 41 )41( 51 sraey 4251
)41( 61 )31( 81 )91( 91 sraey 4352
)31( 61 )22( 91 )02( 91 sraey 4443
61 )71( 71 sraey 4544 (21) )41( 61
91 )51( 41 )31( 31 sraey 4645 (25)
)12( 81 )51( 91 )71( 81 sraey 56
Significant differences
(
CI = 95%
)
between the total population. The subgroup with sleeping problems have been emboldened
© 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1) Omnibus: sleep problems in the general population Léger et al. 311
(95% CI 75–81%) of US respondents and 15% (95% CI
9–21%) of Japanese respondents. The nature of the
predominant symptom remained the same in most cases.
Frequency of sleep problems
Most individuals from Western Europe and the USA
reporting sleep problems experienced symptoms at
least several times per week. In Japan, problems were
less frequent (Figure 2). The majority of respondents
from each region indicated that they had experienced
symptoms for at least 1 year (mean of 6 years, 5 years
and 4 years in Western Europe, the USA and Japan,
respectively). Despite having experienced sleeping
problems for more than 1 year, only 51%, 55% and 52%
of respondents in Western Europe, the USA and Japan,
respectively considered their problems to be chronic
rather than occasional. However, if a chronic sleep
problem is defined as having experienced a symptom
for
1 month, 88% (95% CI 86–90%) of participants
from Western Europe, 93% (95% CI 9096%) from
Japan and 93% (95% CI 92–94%) from the USA would
have been categorized with chronic sleep problems.
This was true for all aspects of sleep disorders (sleep
induction, maintenance and quality).
Impact of sleep problems
Most individuals with sleep problems considered these
to have an impact on their daily functioning (Figure 3),
Figure 1. Types of sleep problems among individuals reporting sleep problems over the previous 12 months. Answers were in
response to the following question: ‘What sleep problem symptoms do you currently suffer from?’. p-values for trends: USA vs.
Western Europe (0.025 < p < 0.05), Western Europe vs. Japan (0.05 < p < 0.1), and USA vs. Japan (
p < 0.005)
57
78
52
55
75
33
69
63
31
0
20
40
60
80
100
Sleep induction problems Sleep maintenance
problems
Poor sleep quality
Sleep problem
Respondents (%)
USA (n = 1637) Western Europe (n = 1306)
Japan (n = 259)
Figure 2. Frequency of sleep problems among individuals reporting sleep problems over the previous 12 months. Answers were in
response to the following question: ‘How often do you have these sleeping symptoms?’. p < 0.005 for between-region differences
4.8
14.0
26.6
13.6
19.0
31.0
52.0
35.0
27.0
29.6
30.0
15.4
0
10
20
30
40
50
60
70
80
90
100
USA
(n = 1637)
Europe
(n = 1306)
Japan
(n = 259)
Region
Respondents (%)
Occasionally A few times per week
A few times per month Every night
312 Omnibus: sleep problems in the general population © 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1)
including family life, personal activities, professional
activities and social relationships (Figure 4). In Japan,
professional activities were the daily function aspect
that were most affected by sleep problems, while
family life was most affected in Western Europe and
personal activities were most affected in the USA. Not
surprisingly, the impact of sleep problems on daily
functioning was linked to the number of symptoms
reported by the individual: 91% (95% CI 8894%)
of US respondents experiencing sleep induction,
maintenance and quality problems considered sleep
to impact their daily function, as did 86% (95% CI
73–99%) of Japanese respondents and 62% (95% CI
56–68%) of Western European respondents.
Chi-squared analysis showed that there were
several demographic or behavioral characteristics that
were common to individuals across the regions who
perceived their sleeping problems to impact their daily
function (Table 2). These included having several
symptoms, experiencing symptoms quite often, and
suffering from sleep-related comorbidities.
The most frequent disorder caused by sleep problems
was physical fatigue, either in the morning or later in
the day. Bad mood, poor concentration and mental
fatigue were also commonly considered to be caused
by sleep problems.
Individuals with sleep problems often had other
comorbidities that may have been associated with
their sleep. In all three regions, stress and overworking
was the most common comorbidity. In the USA,
being overweight was also a dominant comorbidity,
with joint pain/rheumatism, anxiety/anguish and
Figure 4. Perceived consequences of sleep problems on specific aspects of daily functioning. Answers were in response to
completing the following statement: ‘Would you say that your sleep problems impact…?’ p < 0.005 for between-region differences
for each aspect of daily functioning (‘Family life’, ‘Personal activities’, ‘Professional activities’, ‘Social relationships’)
Figure 3. Perceived consequences of sleep problems on daily functioning. Answers were in response to completing the following
statement: ‘Would you say that your sleep problems impact your daily functioning…?’ p < 0.005 for between-region differences
18 18
12
61
36
46
18
27
37
3
19
5
0
10
20
30
40
50
60
70
80
90
100
USA
(n = 1637)
Western Europe
(n = 1306)
Japan
(n = 259)
Region
Respondents (%)
A lot Somewhat
Not really Not at all
© 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1) Omnibus: sleep problems in the general population Léger et al. 313
nervousness/irritability occurring comparatively
frequently in Western European respondents. The two
most common comorbidities in Japanese respondents
were stress/overworking and nervousness/irritability,
although over a quarter of Japanese respondents did
not have an associated comorbidity.
Treatment for sleep problems
Almost half of individuals with sleep problems had never
taken any steps to resolve their sleeping problems. The
majority of respondents reporting a sleep disorder had not
spoken to a physician about it (47% [95% CI 44–50%] in
Western Europe, 65% [95% CI 63–67%] in the USA and
67% [95% CI 61–73%] in Japan). Of those respondents
who had consulted a physician with regard to their sleep
problems, approximately 50% in Western Europe and
the USA received a drug prescription, compared with
90% of respondents in Japan. Of those who received a
prescription drug, the average length of time taking this
treatment was 2 years in the USA, 3 years in Japan and
4 years in Western Europe. In all, 29% of patients in
Western Europe, 10% in the US, and 24% in Japan were
taking the last treatment prescribed for more than 5 years.
Prescription drugs were taken more frequently across
all regions than drugs advised by a pharmacist, drugs
without any medical advice or treatments other than
drugs. In Western Europe, significantly more individuals
with sleep maintenance problems were not receiving any
form of treatment compared with other symptoms (
p <
0.05). In contrast, in the USA, more individuals with
sleep quality symptoms were not receiving treatment
(
p < 0.05). Chi-squared analysis showed that there were
several demographic or behavioral characteristics that
were common to individuals across the regions who had
a medical treatment prescribed for their sleep problems
(Table 3). These included having several symptoms,
considering their sleep problems to be chronic, and
suffering from sleep-related comorbidities. Another
predictive factor was using other strategies to resolve
sleep problems, whether this be non-prescription drugs or
other remedies. While individuals in Western Europe or
the USA were more likely to have experienced a negative
change in their symptoms over time, Japanese individuals
were more likely to have experienced a positive change in
their symptoms.
Discussion
The magnitude of sleep problems in three economically
developed parts of the world (Western Europe, Japan and
USA) is clearly shown in this study. When extrapolated
to the general population, this indicates that 131.3
million
people in the USA
1.5%), 82.3
million people in
Western Europe
1.3%), and 25.6
million people in
Japan
2.4%) have had sleep problems within the past
12 months. Even with a more stringent definition of
insomnia , it still concerns 38.1
million people in the USA
1.1%), 18.8
million people in Western Europe
0.7%)
and 5.2
million people in Japan
1.2%). Clearly Japan
appears to be less effected by sleep problems than the two
other continents. It could be speculated that the lower
prevalence in Japan may be a function of under-reporting
Table 2. Chi-squared analysis showing statistically significant demographic or behavioral characteristics of individuals who
perceive their sleep problems to impact on their daily functioning
USA Western
Europe
Japan
Age ≥
65 years
Female
noitapucco na evaH
Poor sleep quality
Have difficulty falling asleep
Experience several sleep symptoms
Experienced an evolution in sleep problems
Experience problems as a consequence of insomnia
Experience sleep problems quite frequently
Consider their sleep problems to be chronic
Experience comorbidities as a result of sleep problems
Have consulted a physician about sleep problems
smelborp peels tuoba tsirtaihcysp a detlusnoc evaH
Take a prescribed medication or another means of resolving their sleep problems
noitacidem debircserp-non a esU
314 Omnibus: sleep problems in the general population © 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1)
because of the possible cultural reticence among Japanese
people to associate sleep problems and psychiatric
disorders
27
. Indeed, the relatively short mean time spent
in bed (6.5
h) reported previously in the Japanese adult
population
13
might lead to reduced difficulty maintaining
sleep, as bedtime restriction has been shown to improve
sleep efficiency
28
. The prevalence of insomnia we found
in the Japanese is consistent with that found by Doi
and colleagues in a nationwide sample of 2800 subjects:
17.3% in males and 21.5% in females
29
. However in
young people, Kaneita and colleagues recently found in
a survey of 102
451 Japanese adolescents that insomnia
concerns 23.5% of the sample, which was more than in
our study
30
. Interestingly, the reported prevalence in this
study is notably greater than in the previous survey (37%,
27%, 28%, and 6.6% in France, Italy, the USA and Japan,
respectively)
27
. The relatively dramatic difference in the
prevalence in the USA in this study may be a consequence
of an increased awareness and perception of sleeping
problems in the general population due to national public
and private education on sleep disorders; however, it is
interesting that it appears to have had a limited effect on
physician consultation rates or prescriptions. Although
cultural factors are likely to influence responses, the
prevalence in the USA obtained in this study does not
differ substantially from the findings of previous surveys,
in which approximately a third to one-half of respondents
reported sleep disturbances. The 2002 National Sleep
Foundation poll reported that 58% of adults said that they
had at least one symptom of insomnia at least a few times
per week. However, these people did not necessarily
experience daytime sleepiness as a consequence of
their insomnia. The higher prevalence in the Japanese
population in this study compared with the previous
survey may be linked to the inclusion of individuals aged
65 years in the Japanese sample in this study (who were
not included in the previous sample). The prevalence
of sleep problems obtained in the present survey is also
consistent with the findings of a previous epidemiological
study including 3030 participants recruited throughout
Japan
12
. In Western Europe, there has only been a limited
change in the prevalence of insomnia between this survey
and the previous one and the frequency of sleep disorders
and insomnia found in this study are similar to those
reported in previous epidemiological studies carried out
in Western Europe (19–25% for sleep disorders, 9–12%
for severe insomnia)
6,10,31
.
The distribution of sleep problems according to age
varied between regions; in Japan, but not in Western
Europe and in the USA, respondents aged
65 years
experienced a high prevalence of problems. This is not
consistent with previous studies which regularly found
higher percentages of sleep problems in the elderly. We
have no explanation for this unusual result. Conversely
the fact that more females than males reported sleep
problems is consistent with previous studies investigating
the epidemiology of sleep disorders
5–10,32
.
The most frequently reported sleep problem varied
according to region: in Japan, sleep induction was the
most prevalent problem, as was found by Doi et al.
29
,
Table 3. Chi-squared analysis showing statistically significant demographic or behavioral characteristics of individuals who
are prescribed a medical treatment for their sleep problems
nretseW ASU
Europe
Japan
Age ≥
65 years
Female
noitapucco na evaH
Have difficulty falling asleep
sgninekawa emit-thgin ecneirepxE
Experience several sleep symptoms
smelborp peels ni noitulove na decneirepxE
Experienced a negative evolution in sleep problems
Experienced a positive evolution in sleep problems
Experience an impact on daily functioning
Experienced problems as a consequence of insomnia
Have frequent and long-lasting sleep problems
Consider their sleep problems to be chronic
Experience comorbidities as a result of sleep problems
Use sleep remedies frequently
Use a non-prescribed medication
noitacidem fo snaem rehto esU
© 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1) Omnibus: sleep problems in the general population Léger et al. 315
while in Western Europe and the USA, more individuals
had problems with sleep maintenance. Taken together,
it is clear that the most prevalent global sleep problem is
sleep maintenance, with 75
million people in the USA,
51
million people in Western Europe and 15
million
people in Japan likely to report difficulties with sleep
maintenance. The majority of respondents reported
problems with more than one sleep parameter. Sleep
problems changed in severity over time in just under
half of participants in each region: in Western Europe
and the USA, a considerable proportion of respondents
considered that their sleep had deteriorated, while most
Japanese respondents reported their sleep problems
improving over time. Many factors may explain this
change. One simple one is age, as we know that sleep
quality decreases with age
33
. Potential differences in time
spent in bed, which is strongly influenced by the regional
culture and socioeconomic status of the population,
might explain the variation in types of sleep problems
that were reported by participants in this study from
different countries. Environmental issues, transportation
and security consideration may also have an influence on
sleep
34
. We do not have enough sociocultural data in this
study to explain why the development of a sleep disorder
differs from one country to another. Interestingly, while
most sleep problems may have changed in severity, they
rarely changed in nature, with the predominant symptom
remaining the same for most individuals.
One of the most interesting observations from this
survey is the perception that many individuals have
regarding the chronic nature of their sleeping problems.
Almost half of respondents did not consider their
symptoms to be chronic, despite having experienced
them for a considerable length of time. This suggests that
the perception of chronic status may be more linked to
the frequency of the symptom rather than its duration,
and possibly partially explains the under-reporting and
under-treatment of these symptoms.
The relevance of cultural issues with regard to the
concepts explored by the questionnaire, and also in the
observed results are very interesting. Are the differences
observed between countries only due to cultural
habits and perception, or is it possible to say that the
Japanese sleep better than people in other countries? It
is particularly interesting to observe that when patients
with insomnia are recognized in Japan, 90% are treated
with a hypnotic. One hypothesis to explain the difference
would be to imagine that sleep disorders are less frequent
and better treated in Japan. Another would be that, taking
account of cultural issues, the Japanese are less likely to
report/complain of insomnia than Western Europeans
or Americans, and are treated only if the complaints are
severe (particularly if they impact on work ability).
Zammit and colleagues have previously shown that
sleep problems impair ability to perform work and
daily activities
21
, as have several other studies
18,19
. In our
study, chi-squared analysis found a number of common
predictive factors for impairing ability to perform daily
activities across the regions. These included experiencing
several symptoms, experiencing symptoms frequently,
and experiencing problems or comorbidities related to
sleeping problems. In the USA and Western Europe,
those who had impaired daily function were more likely
to take a prescribed medication (hypnotic) or another
means of resolving sleeping problems, whereas in Japan,
individuals were more likely to take other kinds of
medications. This difference may be due to the fact that
Japanese physicians often prefer to use the terms ‘sleep-
inducing drug’, or ‘hypnotic tranquilizer’ rather than
‘hypnotic’ when prescribing benzodiazepines or newer
non-benzodiazepine hypnotics, because in Japan the
term ‘hypnotic’ is associated with the older, relatively
harmful hypnotic barbiturates.
Participants in the USA were more likely to report
a disorder attributed to their sleeping problems,
particularly fatigue or tiredness. Very few participants
considered that they did not have any disorders associated
with their sleeping problems. Stress and overwork were
commonly associated with sleeping problems across all
regions. In the USA, being overweight was a common
association (as has been recently shown by Vorona
et al.
35
), while nervousness and irritability was more
pronounced in Western Europe. Japanese respondents
were more likely to report that they did not have any
associated comorbidity compared with respondents from
Western Europe and the USA. This is possibly a function
of different cultural and societal practices across regions.
Individuals who experienced comorbidities were more
frequently treated for their sleeping problems than those
without comorbidities.
Importantly, and unsurprisingly, this study reinforces
the findings of the previous survey
27
that show that sleep
problems are under-reported and under-treated across
all regions. Extrapolation to the general population
highlights the level of under-treatment: 31.9
million
0.9%), 49.1
million
1.3%), and 8.2
million
1.5%)
people with sleep problems in Western Europe, the
USA, and Japan, respectively, have never taken any steps
to resolve their sleep problems and 49.6
million
1.1%),
80.3
million
1.5%), and 17.2
million
2.1%) people
with sleep problems have not taken a prescription
drug for their sleeping problem in the past 12 months,
respectively. The reasons for this have yet to be clearly
established; however, previous studies have suggested
that this might be attributed to the short duration of
primary-care consultations, lack of recognition of sleep
problems as a medical concern and lack of knowledge
and understanding of available treatments
36–38
. Japanese
respondents who did consult a physician regarding their
sleep problems were considerably more likely to receive a
316 Omnibus: sleep problems in the general population © 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1)
prescription medication than those in Western Europe or
the USA. Those who experienced several sleep symptoms,
who considered their problems to be chronic, or who
experienced comorbidities as a result of sleep problems,
were more likely to receive a drug prescription across all
regions. Interestingly, those in Japan who experienced
an improvement in their symptoms were more likely to
have a prescription medication, whereas those in Western
Europe and the USA who experienced a worsening were
more likely to have a prescription medication for their
sleep problems. This difference may be due to the time
restriction of 28 days for the prescription of hypnotics in
Western Europe which means that when sleep problems
and comorbidities improve, physicians tend to limit the
prescription.
As a result of the international scope of this project,
the study had several limitations.
Different types of interviewing technique (internet,
telephone or questionnaires via post) were used
depending on the country and may impact the results
obtained. We understand that these different techniques
of interviewing people may deeply impact the responses
of subjects and that it is a limitation of the study.
However, these different techniques were used in an
attempt to follow the cultural habits of each participating
country and to try and match as closely as possible
the usual conventions of interviewing people. Several
comparative studies have also shown that using DC
channel is low. When asking a respondent if they have
difficulties falling asleep, the answer is similar by phone,
by post, or by internet. However, if the DC channel is
not adapted to the specific culture of each country,
the risk of introducing a bias in the recruitment is high
(particularly with an elderly population).
The authors are also conscious that interviewing
people about sleep problems may substantially influence
their answer on daytime correlates and functioning. It is,
however, difficult to avoid this kind of bias in focused
epidemiological studies.
We also understand that the translation of the
questionnaire into different languages is a very difficult
issue. Local questionnaires have been validated by sleep
specialists and double-checked by the national poll
institutes on the linguistic aspect. However we did not
use the complete process of validating a questionnaire
(translation forward and translation backward, use in
pilot group…) and it is possible that this limitation had
an impact on the differences found between countries.
Another issue is excluding subjects suffering from
other sleep troubles from the survey. We are conscious
that sleep apnea and restless legs syndrome are
underdiagnosed and that people may not be conscious
that their sleep disorders may be related to them.
However this study was not based on objective measures
of sleep, and it was not possible to avoid this bias.
The results of the five European countries were
combined in this paper to aid the comprehension of the
global results. We believe, however, that it would be of
value in a future paper to show the differences between
these culturally different countries in more detail.
Conclusions
In conclusion, this survey highlights the considerable
burden of sleep problems across Europe, the USA and
Japan, with sleep maintenance of particular concern to
individuals in Western Europe and the USA and sleep
induction a particular issue in Japan. Sleep problems
continue to be under-reported and under-treated.
While Japanese individuals who consult their physician
about their sleeping problems generally receive a drug
prescription, only half of those in Western European or
the USA who consult their doctor are likely to receive a
prescription, even if they complain about deterioration
in their ability to perform daily activities. Primary
care physicians may be the most effective means of
diagnosing sleep problems in their patients and initiating
the appropriate treatment strategy; however, greater
education and provision of guidelines for primary care
physicians may be required to ensure that this occurs.
Future research focusing on the impact of educating
primary care physicians on the prevalence and severity of
chronic insomnia would be of value.
Acknowledgments
This manuscript was supported by an educational
grant from Sanofi-Aventis; editorial assistance, funded
by Sanofi-Aventis, was provided by Joseph Mole and
Matthew Weitz.
Declaration of interest: Dr Léger has served as a
consultant to Sanofi-Aventis, Lundbeck, GSK and Takeda.
Dr Poursain is a consultant for the pharmaceutical industry
(several major pharmaceutical companies) as an expert in
Market Research & Business Intelligence. Dr Neubauer
has served as a consultant to Neurocrine Biosciences,
Pfizer, Sanofi-Aventis and Takeda Pharmaceuticals. Dr
Uchiyama is a medical expert for Takeda Pharmaceuticals,
Astellas and Integrated Development Associates; and is a
consultant for Banyu Pharmaceuticals.
All authors have participated in the design and the
analysis of this study.
References
1. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4 edn. Washington, DC: American
Psychiatric Association, 1994
© 2008 LIBRAPHARM LTD – Curr Med Res 2008; 24(1) Omnibus: sleep problems in the general population Léger et al. 317
2. Chesson A, Jr., Hartse K, Anderson WM, et al. Practice
parameters for the evaluation of chronic insomnia. An American
Academy of Sleep Medicine report. Standards of Practice
Committee of the American Academy of Sleep Medicine. Sleep
2000;23:237-41
3. Insomnia: assessment and management in primary care. Sleep
1999;22(Suppl 2):S402-8
4. Edinger JD, Bonnet MH, Bootzin RR, et al. Derivation of research
diagnostic criteria for insomnia: report of an American Academy
of Sleep Medicine Work Group. Sleep 2004;27:1567-96
5. Ohayon MM. Epidemiology of insomnia: what we know and
what we still need to learn. Sleep Med Rev 2002;6:97-111
6. Ohayon MM. Prevalence and correlates of nonrestorative sleep
complaints. Arch Intern Med 2005;165:35-41
7. Ohayon MM, Roth T. What are the contributing factors
for insomnia in the general population? J Psychosom Res
2001;51:745-55
8. Ohayon MM, Smirne S. Prevalence and consequences of
insomnia disorders in the general population of Italy. Sleep Med
2002;3:115-20
9. Ohayon MM, Zulley J. Correlates of global sleep dissatisfaction
in the German population. Sleep 2001;24:780-7
10. Léger D, Guilleminault C, Dreyfus JP, et al. Prevalence of
insomnia in a survey of 12,778 adults in France. J Sleep Res
2000;9:35-42
11. Kim K, Uchiyama M, Liu X, et al. Somatic and psychological
complaints and their correlates with insomnia in the Japanese
general population. Psychosom Med 2001;63:441-6
12. Kim K, Uchiyama M, Okawa M, et al. An epidemiological
study of insomnia among the Japanese general population. Sleep
2000;23:41-7
13. Liu X, Uchiyama M, Kim K, et al. Sleep loss and daytime
sleepiness in the general adult population of Japan. Psychiatry
Res 2000;93:1-11
14. Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health
risk factor. Behav Sleep Med 2003;1:227-47
15. Okuji Y, Matsuura M, Kawasaki N, et al. Prevalence of insomnia
in various psychiatric diagnostic categories. Psychiatry Clin
Neurosci 2002;56:239-40
16. Katz DA, McHorney CA. Clinical correlates of insomnia
in patients with chronic illness. Arch Intern Med
1998;158:1099-107
17. Gander PH, Marshall NS, Harris RB, Reid P. Sleep, sleepiness
and motor vehicle accidents: a national survey. Aust N Z J
Public Health 2005;29:16-21
18. Léger D, Guilleminault C, Bader G, et al. Medical and socio-
professional impact of insomnia. Sleep 2002;25:625-9
19. Metlaine A, Léger D, Choudat D. Socioeconomic impact of
insomnia in working populations. Ind Health 2005;43:11-19
20. Baldwin CM, Griffith KA, Nieto FJ, et al. The association of
sleep-disordered breathing and sleep symptoms with quality of
life in the Sleep Heart Health Study. Sleep 2001;24:96-105
21. Zammit GK, Weiner J, Damato N, et al. Quality of life in
people with insomnia. Sleep 1999;22(Suppl 2):S379-85
22. Léger D, Scheuermaier K, Philip P, et al. SF-36: evaluation of
quality of life in severe and mild insomniacs compared with
good sleepers. Psychosom Med 2001;63:49-55
23. Walsh JK, Engelhardt CL. The direct economic costs of
insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):
S386-93
24. Léger D, Levy E, Paillard M. The direct costs of insomnia in
France. Sleep 1999;22(Suppl 2):S394-401
25. Chilcott LA, Shapiro CM. The socioeconomic impact of
insomnia. An overview. Pharmacoeconomics 1996;10
(Suppl 1):1-14
26. Estivill E. Behaviour of insomniacs and implication for
their manage ment. Sleep Med Rev 2002;6(Suppl 1):
S3-6
27. Léger D, Poursain B. An international survey of insomnia:
under-recognition and under-treatment of a polysymptomatic
condition. Curr Med Res Opin 2005;21:1785-92
28. Guilleminault C, Powell NB, Martinez S, et al. Preliminary
observ ations on the effects of sleep time in a sleep restriction
paradigm. Sleep Med 2003;4:177-84
29. Doi Y, Minowa M, Okawa M, Uchiyama M. Prevalence of
sleep disturbance and hypnotic medication use in relation
to sociodemographic factors in the general Japanese adult
population. J Epidemiol 2000;10:79-86
30. Kaneita Y, Ohida T, Osaki Y, Tanihata T, Minowa M,
Suzuki K, Wada K, Kanda H, Hayashi K. Insomnia among
Japanese adolescents: a nationwide representative survey. Sleep.
2006;29:1543-50
31. Chevalier H, Los F, Boichut D, et al. Evaluation of severe
insomnia in the general population: results of a European
multinational survey. J Psychopharmacol 1999;13(4 Suppl 1):
S21-4)
32. Kawada T, Yosiaki S, Yasuo K, Suzuki S. Population study on
the prevalence of insomnia and insomnia-related factors among
Japanese women. Sleep Med 2003;4:563-7
33. Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and
aging 2: Management of sleep disorders in older people. CMAJ
2007;176:1449-54
34. Rashke F. Arousals and aircraft noise - environmental disorders
of sleep and health in terms of sleep medicine. Noise Health
2004;6:15-26
35. Vorona RD, Winn MP, Babineau TW, et al. Overweight and
obese patients in a primary care population report less sleep
than patients with a normal body mass index. Arch Intern Med
2005;165:25-30
36. Neubauer DN. Insomnia. Prim Care 2005;32:375-88
37. Doghramji PP. Recognizing sleep disorders in a primary care
setting. J Clin Psychiatry 2004;65(Suppl 16):23-6
38. Billiard M, Bentley A. Is insomnia best categorized as a symptom
or a disease? Sleep Med 2004;5(Suppl 1):S35-40
CrossRef links are available in the online published version of this paper:
http://www.cmrojournal.com
Paper CMRO-3615_4, Accepted for publication: 05 November 2007
Published Online: 07 December 2007
doi:10.1185/030079908X253771
Appendix
A detailed description of the questionnaire used for this study is available as electronic supplementary data
(doi:10.1185/030079908X253825) published with the online version of this article.
... Higher MEQ scores reflect stronger preference for morningness ("morning-oriented types", M-types) and lower scores reflect stronger preference for eveningness ("evening-oriented types", E-types). Based on the overall score, five categories can be identified, namely: (i) definitely E-type (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), (ii) moderately E-type (31-41), (iii) neither type or Intermediate-type (I-type) (42-58), (iv) moderately M-type (59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69), and (v) definitely M-type (70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84)(85)(86). For ease of interpretation, we considered moderately E-type as E-type (16-41 points) and moderately M-type as M-type (59-86 points). ...
... This finding is quite in line with previous reports, which used the same measurement tool [19,20,64]. Comparing the prevalence of sleep disturbance among the included psoriatic patients with that recorded in the general population, which is estimated to range between 30 and 50% [65], impairment of sleep quality appears to be much more common in subjects affected with psoriasis. Therefore, our data confirm the sleep problems that have been previously revealed by a number of studies among psoriatic patients [23]. ...
Article
Full-text available
Background: Psoriasis is an inflammatory disease for which the implications and repercussions go far beyond the skin. Psoriasis patients suffer not only due to its skin manifestations and related symptoms but also because of comorbidities and a huge emotional impact. Objective: The objective of this study was to investigate chronotype and sleep quality in a group of Italian psoriatic patients. Materials and Methods: An observational, cross-sectional, web-based study was set up by the Dermatology and Clinical Medicine Sections of the Department of Medical Sciences, University of Ferrara, Italy. The web questionnaire was sent to an email list of an Italian association of psoriatic patients with the aim of recording their main demographic, social, historical, and clinical data. The survey included two questionnaires: the Morningness–Eveningness Questionnaire (MEQ) and the Pittsburg Sleep Quality Index (PSQI). Results: Two hundred and forty-three psoriatic patients (mean age 52.9 ± 12.8 yrs., 32.5% males and 67.5% females) filled out the questionnaire. A good 63.8% of them were affected with psoriasis for more than 10 years, 25.9% reported having a diffuse psoriasis, and 66.7% were on treatment at the time they completed the questionnaire. With reference to chronotype, the mean MEQ score was 55.2 ± 10.7; furthermore, 44% of the patients were “morning-oriented types”, M-types, or “larks”, 44.5% were “intermediate-types” or I-types, and 11.5% were “evening-oriented types”, E-types, or “owls”. No correlations were found between chronotype and psoriasis extension. Based on the PSQI results, 72.8% of the study population was judged to have a low sleep quality. Sleep disturbance was significantly related to female sex, living alone, and the presence of comorbidities. Conclusions: Sleep disturbance is very common in psoriatic patients, especially in those with comorbidities, in females, and in patients who live alone. The chronotype in psoriatic patients does not appear different when compared to the general population, nor does it seem to have any link with psoriasis severity.
... Another variable to consider is the potential variation in the prevalence of sleep disturbance among our sample of individuals who have experienced a high level of childhood adversity compared to the general population. According to previous research, the prevalence of sleep problems in the general population varies between 20 to 41.7% 90 , while Western Europe reports a prevalence of 31% 91 . The observed prevalence of 30%-as determined by a screening question on the Structured Clinical Interview for DSM-5 (SCID-5 92 ) aligns with the global range of prevalence. ...
Article
Full-text available
Children in institutional care have a high risk to experience childhood adversities (CAs), with consequences for physical and mental well-being. The long-term effects of CAs on the brain, including consequences for neuronal plasticity and sleep, are poorly understood. This study examined the interplay between stress (including CAs), sleep, and brain-derived neurotrophic factor (BDNF), a prominent marker for neuronal plasticity. Participants ( N = 131, mean age = 26.3±3.4 years, 40 females) with residential youth-care history completed questionnaires measuring CAs (Childhood Trauma Questionnaire, CTQ), psychological well-being (World Health Organization-Five Well-Being Index, WHO-5), and sleep disturbances (Pittsburgh Sleep Quality Inventory, PSQI). Hair cortisol and serum BDNF concentration were measured using enzyme-linked immunosorbent assays. The analyses were conducted by using bootstrap regression models. There was no association of stress parameters or sleep with BDNF concentration. However, we found a significant association of CAs and well-being with sleep disturbances. Last, we found an association between CAs and BDNF in sleep-healthy but not sleep-disturbed participants. Our findings indicated a role of sleep disturbance in the association between stress and BDNF. Still, further studies are warranted using vulnerable groups at-risk to understand long-term effects on mental health and sleep.
... One international survey from 2008 estimated that the prevalence of sleeping problems was 56% in the United States, 31% in western Europe, and 23% in Japan. 7 Another study published in 2012 found striking regional variation across Ghana, Tanzania, South Africa, India, Bangladesh, Vietnam, Indonesia, and Kenya, but an overall prevalence of 16.6% of severe to extreme sleep problems. 8 Specific sleep disorders such as sleep apnoea affect more than 936 million people worldwide; insomnia has been found to affect up to 30% of adults. ...
... To cope with the aging of the population, the government is requiring companies to try to retain their employees until the age of 70 under the revision Act on Stabilization of Employment of Elderly Persons from April 2021. There is concern that as the number of people with sleep problems increases with age (see, for example, Léger et al. [45], Dregan and Armstrong, [46,47], van de Straat and Bracke [5]), their productivity will also be affected. According to the National Survey on Basic Living Conditions (Ministry of Health, Labour and Welfare 2019), the proportion of people who do not get enough rest from sleep, as mentioned at the beginning of this paper, is reported to increase with age. ...
Article
Full-text available
Based on a randomized controlled trial applied to employees of a manufacturing company, this study examines the extent to which a corporate sleep program improves workers’ sleep health and productivity. In the three-month sleep improvement program, applicants were randomly divided into a treatment group and a control group, and the treatment group was provided with a noncontact sensing device to visualize their sleep. A smartphone app linked to the device notified them of their sleep data every morning and presented them with advice on behavioral changes to improve their sleep on a weekly basis. The results of the analysis revealed the following. First, even after controlling for factors that may cause sleep disturbances and nocturnal awakenings, such as increased workload and the number of days spent working from home during the measurement period, the treatment group showed improved sleep after the program compared to the control group. Second, the treatment group showed statistically significant improvement in presenteeism (productivity). The effect size on presenteeism through sleep improvement was similar regardless of the estimation method used (i.e., ANCOVA estimator of ATT and two 2SLS methods were performed). In particular, we confirmed that productivity was restored through sleep improvement for the participants who diligently engaged in the program. These results suggest that promoting sleep health using information technology can improve sleep deficiency and restore productivity.
... 21 An international survey of sleeping problems in the general population revealed that the prevalence of sleeping problems was 56% in the USA, 31% in Western Europe and 23% in Japan. 22 In South Africa, 31.3% of women and 27.2% of men reported difficulty with sleeping. Overall rates of sleep problems in the remaining African nations of Tanzania, Ghana and Kenya ranged between 8.3% and 12.7%. ...
Article
Full-text available
Objective This study aimed to investigate the prevalence and associated factors of poor sleep quality among Bole Lemi Industrial Park workers in Addis Ababa, the capital of Ethiopia. Design An institution-based cross-sectional study was conducted from July to August 2022. The data were collected using a validated and standardised Pittsburgh Sleep Quality Index Questionnaire. The collected data were entered into EpiData V.4.6 and analysed using Stata V.14. A multivariable binary logistic regression analysis was conducted to identify factors associated with poor sleep quality. The association was determined using an adjusted OR (AOR) with a 95% CI at a p value of <0.05. Setting The study was conducted in Bole Lemi Industrial Park in Addis Ababa. Participants A total of 370 workers participated in this study. Outcome measures The primary outcome of the study was the prevalence of poor sleep quality. Results The total response rate was 87.7%. The majority (260, 70.3%) of the participants were female. The mean (±SD) age of the participants was 30.5 (±10.6) years. The prevalence of poor sleep quality during the last months was found to be 75.4% (n=279) (95% CI: 70.7% to 79.7%). Undiversified dietary intake (AOR: 1.63; 95% CI (1.09 to 2.78)), caffeine consumption more than 250 mg per day (AOR: 2.57; 95% CI (1.12 to 6.05)) and night shift work (AOR: 2.36; 95% CI (1.27 to 4.41)) were risk factors for poor sleep quality among sampled workers. Conclusion This study detected that poor sleep quality is highly prevalent among garment and textile industry workers, indicating that it is a significant public health issue that requires immediate attention. Therefore, modifications of the work environment involving night shift work and the improvement of workers’ personal lifestyles involving dietary diversification and caffeine consumption are needed to minimise the burden of poor sleep quality among workers.
... In recent decades, sleep disorders have become a worldwide pandemic 3,4 , but many individuals are unaware of the importance of their sleep habits. According to studies, the global prevalence of sleep disorders ranged from 1.6 to 56% 5,6 , with an increasing rate in most populations 7,8 . Numerous common negative outcomes have been associated with sleep difficulties. ...
Article
Full-text available
Nutrient pattern analysis is an easy way to compare nutrient intakes across different nations due to the universality of nutrients nature. The purpose of this study was to examine the relationship between dietary nutrient patterns (NPs) and circulating 25(OH)D concentrations with sleep duration and sleep quality among Iranian adults. We used a multistage cluster random sampling method to enroll 535 adults in this cross-sectional investigation. A validated food frequency questionnaire was applied to evaluate typical dietary intakes. Fasting blood samples were obtained to determine levels of circulating 25(OH)D. Sleep characteristics were assessed using the Pittsburgh Sleep Quality Index (PSQI). Participants had a mean age of 42.57 years and 51.2% of them had insufficient or deficient levels of serum vitamin D. Three NPs were identified: "high animal protein", "high vegetable" and "high carbohydrate". After adjustments for potential confounders, no significant associations were observed between "high animal protein" pattern and short sleeping or sleep quality. Greater adherence to "high vegetable" NP was associated with lower odds of short sleeping (OR 0.24; 95% CI 0.10, 0.54) and poor sleep quality (OR 0.45; 95% CI 0.20, 1.05). Stratified analysis revealed that these associations were stronger in normal-weight participants. Greater adherence to "high carbohydrate" NP, on the other hand, was connected to higher odds of short sleeping (OR 2.83; 95% CI 1.20, 6.72). Low adherence to "high vegetable" pattern and vitamin D insufficiency/deficiency were jointly associated with increased odds of short sleeping (OR 3.42, 95% CI 1.42, 6.64). High adherence to pattern comprising mainly of vegetable nutrients was associated with a reduced likelihood of being short sleepers and having poor sleep quality in Iranian adults, especially among those with a normal weight. Lower adherence to vegetable NP and insufficient/deficient vitamin D levels were synergistically associated with greater likelihood of being short sleepers. Greater adherence to carbohydrate NP was associated with an increased likelihood of short sleeping.
Article
To date, there is scarce evidence on the association between sleep disorders and noise generated by wind turbines. We searched six relevant electronic databases from the inception to May 2023 for relevant articles. The methodological quality of the included articles was evaluated using the US National Institutes of Health tool. Fifteen articles met the inclusion criteria. The overall prevalence of sleep disorders among residents close to wind turbines was 34% (95% Confidence Interval, 0.22–0.47). Univariate meta-regressions for distance and sound power level showed that at higher distance the prevalence of sleep disorders decreases (p = 0.010) and with a higher sound power level the prevalence increases (p = 0.037). Furthermore, this systematic review and meta-analysis highlighted that the overall quality of current research on this topic is poor, and the methods to measure the results are often based on subjective assessments and not validated questionnaires. In conclusion, our preliminary findings suggest that there may be a possible relation between exposure to wind turbines and sleep disorders, although no conclusions can be drawn in terms of causality due to the nature of the retrieved data and the poor quality of current evidence. Future studies should adopt a longitudinal design and focus on objective measurements, supported by validated subjective methods such as questionnaires.
Article
Sleep loss impairs cognition; however, individuals differ in their response to sleep loss. Current methods to identify an individual's vulnerability to sleep loss involve time‐consuming sleep‐loss challenges and neurobehavioural tests. Here, we sought to identify electroencephalographic markers of sleep‐loss vulnerability obtained from routine night sleep. We retrospectively analysed four studies in which 50 healthy young adults (21 women) completed a laboratory baseline‐sleep phase followed by a sleep‐loss challenge. After classifying subjects as resilient or vulnerable to sleep loss, we extracted three electroencephalographic features from four channels during the baseline nights, evaluated the discriminatory power of these features using the first two studies (discovery), and assessed reproducibility of the results using the remaining two studies (reproducibility). In the discovery analysis, we found that, compared to resilient subjects, vulnerable subjects exhibited: (1) higher slow‐wave activity power in channel O1 ( p < 0.0042, corrected for multiple comparisons) and in channels O2 and C3 ( p < 0.05, uncorrected); (2) higher slow‐wave activity rise rate in channels O1 and O2 ( p < 0.05, uncorrected); and (3) lower sleep spindle frequency in channels C3 and C4 ( p < 0.05, uncorrected). Our reproducibility analysis confirmed the discovery results on slow‐wave activity power and slow‐wave activity rise rate, and for these two electroencephalographic features we observed consistent group‐difference trends across all four channels in both analyses. The higher slow‐wave activity power and slow‐wave activity rise rate in vulnerable individuals suggest that they have a persistently higher sleep pressure under normal rested conditions.
Article
Caffeine, which shares consubstantial structural similarity with purine adenosine, has been demonstrated as a nonselective adenosine receptor antagonist for eliciting most of the biological functions at physiologically relevant dosages. Accumulating evidence supports caffeine's beneficial effects against different disorders, such as total cardiovascular diseases and type 2 diabetes. Conversely, paradoxical effects are also linked to caffeine ingestion in humans including hypertension–hypotension and tachycardia–bradycardia. These observations suggest the association of caffeine action with its ingested concentration and/or concurrent interaction with preferential molecular targets to direct explicit events in the human body. Thus, a coherent analysis of the functional targets of caffeine, relevant to normal physiology, and disease pathophysiology, is required to understand the pharmacology of caffeine. This review provides a broad overview of the experimentally validated targets of caffeine, particularly those of therapeutic interest, and the impacts of caffeine on organ‐specific physiology and pathophysiology. Overall, the available empirical and epidemiological evidence supports the dose‐dependent functional activities of caffeine and advocates for further studies to get insights into the caffeine‐induced changes under specific conditions, such as asthma, DNA repair, and cancer, in view of its therapeutic applications.
Article
Objectives: Previous studies that focussed on sleep disturbance have primarily examined specific aspects of sleep disorders rather than considering overall sleep quality. We aimed to investigate different sleep disorders and their combination as risk factors for different types of cancer. Study design: Prospective cohort study. Methods: In this prospective cohort study, we included 78,232 participants. A self-reported questionnaire was used to address insomnia, daytime sleepiness, snoring, and sleep duration. Overall sleep quality was evaluated by summarising these four sleep parameters. Cox proportional hazards analysis was used to estimate the hazard ratios and their 95% confidence intervals for determining the effect of the overall sleep-quality score and its components on the risk of incident cancer. Results: During a median follow-up of 5.67 years, 1266 participants were diagnosed with incident cancer. Compared to participants in the best sleep-quality score group, participants in the worst sleep-quality score group had a higher subsequent risk of overall cancer, and colorectal, breast, uterine or uterine cervical, prostatic, kidney, and bladder cancer. Participants with insomnia and snoring status had an elevated risk of head and neck, breast, uterine or uterine cervical, prostatic, kidney, bladder cancer, and lymphoma. Conclusions: Poor overall sleep-quality scores as well as poor scores for the scale's components, including insomnia and snoring status, elevated the risk of overall and several specific-site cancers. Trial registration: Kailuan Study, ChiCTR2000029767. Registered 12 February, 2020-Retrospectively registered, https://www.chictr.org.cn/showprojEN.html?proj=48316.
Conference Paper
Study Objectives: To assess the direct economic costs of insomnia in the United States in 1995. Methods: The costs of prescription medications were based on 1995 data compiled by IMS America, Ltd. (Plymouth Meeting, PA). Non-prescription medication expenditures were provided by Information Resources, Inc. (Chicago, IL). The costs of physician visits related to insomnia were estimated from unpublished data of the 1994 National Ambulatory Medical Care Survey conducted by the National Center for Health Statistics and from the America Medical Association Center for Health Policy Research. Several other sources were used for other cost estimates. Results: Total cost for substances used to treat insomnia was $1.97 billion, less than half of which was for prescription medication. Health care services for insomnia totaled $11.96 billion, 91% of which is attributable to nursing home care. The total direct costs in the United States for insomnia in 1995 were estimated to be $13.9 billion. Conclusions: Increased efforts are needed in several domains to offset the cost of insomnia including clinical research on the consequences of untreated and treated insomnia, development and implementation of curricula to provide knowledge about sleep and sleep disorders for medical students, physicians, and other health professionals, education to increase public awareness of insomnia and sleep disorders, and more support for basic research on neural mechanisms involved in healthy and disordered sleep.
Conference Paper
Narcolepsy is a disabling neurologic condition affecting I in 2000 individuals, characterized by sleepiness, cataplexy, and transitions from wakefulness into rapid-eye-movement sleep. Current treatments include amphetamine-like stimulants and antidepressants. Human narcolepsy is HLA-associated, multigenic, and environmentally influenced. Positional cloning was used to isolate narcolepsy genes in canine families with autosomal recessive narcolepsy transmission. Three mutations in the G-protein-coupled hypocretin (orexin) receptor-2 (Hcrtr-2) gene were identified. In humans, most cases of narcolepsy are not linked to hypocretin (Hert) ligand or receptor mutations but are associated with undetectable cerebrospinal fluid Hcrt-1 levels. A single Hert gene/narcolepsy mutation was identified in narcoleptic patients. Hcrt-1 is wake-promoting in vivo, and studies in sporadic human narcolepsy indicate a loss of brain Hcrt-1 and Hcrt-2 and a disappearance of Hcrt-1-containing cells in the hypothalamus. Narcolepsy with cataplexy may therefore be due to Hcrt deficiency. The HLA association in humans suggests possible autoimmune activity against hypothalamic Hcrt-containing cells. Hypocretins may also have roles in regulating normal sleep, appetite, neuroendocrine function and energy metabolism, uniquely positioning them as a link between multiple important behaviors. Abnormal Hcrt transmission is also found in neurologic disorders featuring excessive daytime sleepiness and/or hypothalamic abnormalities. Pharmacologic manipulations of Hcrts may have multiple therapeutic applications.
Article
Chronic insomnia is the most common sleep complaint which health care practitioners must confront. Most insomnia patients are not, however, seen by sleep physicians but rather by a variety of primary care physicians. There is little agreement concerning methods for effective assessment and subsequent differential diagnosis of this pervasive problem. The most common basis for diagnosis and subsequent treatment has been the practitioner's clinical impression from an unstructured interview. No systematic, evidence-based guidelines for diagnosis exist for chronic insomnia. This practice parameter paper presents recommendations for the evaluation of chronic insomnia based on the evidence in the accompanying review paper. We recommend use of these parameters by the sleep community, but even more importantly, hope the large number of primary care physicians providing this care can benefit from their use. Conclusions reached in these practice parameters include the following recommendations for the evaluation of chronic insomnia. Since the complaint of insomnia is so widespread and since patients may overlook the impact of poor sleep quality on daily functioning, the health care practitioner should screen for a history of sleep difficulty. This evaluation should include a sleep history focused on common sleep disorders to identify primary and secondary insomnias. Polysomnography, and the Multiple Sleep Latency Test (MSLT) should not be routinely used to screen or diagnose patients with insomnia complaints. However, the complaint of insomnia does not preclude the appropriate use of these tests for diagnosis of specific sleep disorders such as obstructive sleep apnea, periodic limb movement disorder, and narcolepsy that may be present in patients with insomnia. There is insufficient evidence to suggest whether portable sleep studies, actigraphy, or other alternative assessment measures including static charge beds are effective in the evaluation of insomnia complaints. Instruments such as sleep logs, self-administered questionnaires, symptom checklist, or psychological screening tests may be of benefit to discriminate insomnia patients from normals, but these instruments have not been shown to differentiate subtypes of insomnia complaints.
Article
This study was an epidemiological questionnaire survey of a representative sample of the French population that included 12 778 individuals and in which adapted DSM-IV criteria for the definition of insomnia were used. Our goals were not only to assess the prevalence of ‘insomnia’ using these criteria, but also to compare the results obtained with those of prior studies using different definitions of ‘insomnia’. The aim of this study was also to identify where areas of agreement and disaggreement existed, as we believe that it is important to emphasize these points because DSM-IV recommendations are supposedly reflected in clinical practice. Seventy-three per cent of the individuals surveyed complained of a nocturnal sleep problem, but only 29% reported at least one sleep problem three times per week for a month, and 19% (2428 subjects) had at least one sleep problem three times per week for a month and complained of daytime consequences (DSM-IV criteria). Only 9% had two or more nocturnal sleep problems with daytime consequences and were classified as ‘severe insomniacs’. Our study indicates that if DSM-IV criteria are used, the diagnosis of ‘insomnia’ is lower than in other epidemiological studies. The DSM criteria have an advantage in that they emphasize the daytime consequences of nocturnal sleep disturbances, which seem to be responsible for the most important socio-economic costs of the problem.
Article
Patients with chronic insomnia are more likely to develop affective disorders, cardiac morbidity, and other adverse health outcomes, yet many clinicians tend to trivialize the complaint of insomnia or to attribute it only to psychiatric causes. To estimate the prevalence and longitudinal course of insomnia in patients with documented chronic medical illness and/or depression and to quantify the associations between specific chronic conditions and insomnia. The presence of mild or severe insomnia was based on responses to a sleep questionnaire completed by 3445 patients with at least 1 of 5 physician-identified chronic conditions (hypertension, diabetes, congestive heart failure, myocardial infarction, or depression) at baseline; a subsample of 1814 patients completed follow-up questionnaires at 2 years. Using multivariate techniques, we evaluated the relationship between chronic conditions, patient-reported comorbidities, and insomnia (complaints of initiating and maintaining sleep), adjusting for sociodemographics and health habits. Sixteen percent of study patients had severe and 34% had mild insomnia at baseline. At 2-year follow-up, 59% (95% confidence interval, 55%-63%) of patients with mild insomnia and 83% (95% confidence interval, 78%-88%) of patients with severe insomnia at baseline still had sleep problems. Odds ratios corresponding to mild and severe insomnia for key risk factors were as follows: current depressive disorder, 2.6 and 8.2; subthreshold depression, 2.2 and 3.4; congestive heart failure, 1.6 and 2.5; obstructive airway disease, 1.6 and 1.5; back problems, 1.4 and 1.5; hip impairment, 2.2 and 2.7; and prostate problems, 1.6 and 1.4. The majority of insomnia-comorbidity associations observed at baseline persisted at 2-year follow-up. Patients with insomnia require follow-up, as the majority continue to be bothered by difficulty initiating and maintaining sleep. In addition to detecting affective disorders in patients with insomnia, clinicians should focus on medical conditions that disturb sleep, especially cardiopulmonary disease, painful musculoskeletal conditions, and prostate problems.
Article
Insomnia is an extremely common symptom both de novo and in the context of other medical and psychiatric disorders. The impact of insomnia is often ignored both by the individual and by society in terms of its clinical and socioeconomic ramifications. Insomnia is therefore under-appreciated and almost certainly under-treated, thus making it a serious health concern. It is estimated that more than 60 million Americans suffer from insomnia annually, and this figure is expected to grow to 100 million by the middle of the 21st century. Whether it be difficulty initiating or maintaining sleep, the disruption of nocturnal sleep will invariably impact on daytime activities and often results in daytime fatigue, performance deficits (including memory and other cognitive deficits), an increase in the number of sick days taken by an individual and accidents (some catastrophic). This review examines the costs directly related to insomnia in various sectors of healthcare, the indirect costs associated with accidents, sick days and decreased work productivity, and related costs resulting from insomnia but which meet neither the criteria of direct nor indirect cost categories. The total direct, indirect and related costs of insomnia are conservatively estimated at $US30 to 35 billion annually in the US (1994 dollars). Economic gains can be made by treating patients on an outpatient basis in sleep centres.
Article
Several reports indicate that use of hypnotics is significantly higher in France relative to other European countries, but few reports exist concerning the cost of this high consumption of psychotropic medications. The purpose of the present study was to estimate the direct costs that may be attributed to insomnia in France. Data were derived from previously published surveys in this field. It includes the cost of sleep medications and of substances used to promote sleep, outpatient visits to physicians or to other health professionals and sleep recordings and treatment by sleep specialists. The final estimate of the total direct cost of insomnia in France in 1995 was FF 10,232,992,500 ($2,067,271,100). Public authorities have to understand that an increase in the direct costs of insomnia may be balanced by the reduction of the daytime consequences of insomnia and then by the reduction of the indirect costs of insomnia.
Article
To assess the direct economic costs of insomnia in the United States in 1995. The costs of prescription medications were based on 1995 data compiled by IMS America, Ltd. (Plymouth Meeting, PA). Non-prescription medication expenditures were provided by Information Resources, Inc. (Chicago, IL). The costs of physician visits related to insomnia were estimated from unpublished data of the 1994 National Ambulatory Medical Care Survey conducted by the National Center for Health Statistics and from the America Medical Association Center for Health Policy Research. Several other sources were used for other cost estimates. Total cost for substances used to treat insomnia was $1.97 billion, less than half of which was for prescription medication. Health care services for insomnia totaled $11.96 billion, 91% of which is attributable to nursing home care. The total direct costs in the United States for insomnia in 1995 were estimated to be $13.9 billion. Increased efforts are needed in several domains to offset the cost of insomnia including clinical research on the consequences of untreated and treated insomnia, development and implementation of curricula to provide knowledge about sleep and sleep disorders for medical students, physicians, and other health professionals, education to increase public awareness of insomnia and sleep disorders, and more support for basic research on neural mechanisms involved in healthy and disordered sleep.
Article
To determine whether subjects with insomnia report greater reductions in quality of life (QoL) than subjects without insomnia when assessed with self-report instruments. Questionnaires were completed by individuals recruited through media advertisements and screened with a structured telephone interview. Data obtained from 261 individuals with insomnia (INS group) were compared with those of 101 individuals with no sleep complaint, or controls (CTL group). Subjects in the INS group obtained lower mean sum scores on the Medical Outcomes Study Cognitive Scale than did subjects in the CTL group (25.34 +/- 0.34 vs 31.91 +/- 0.58, t = 9.53, p < 0.0001). The INS group also obtained lower mean scores on all subscales of the SF-36 Questionnaire compared with those in the CTL group (each, p < 0.0001 or lower), indicating impairments across multiple QoL domains. Psychiatric assessment revealed that subjects in the INS group obtained significantly higher mean item scores than subjects in the control group on the Zung Depression Scale (2.22 +/- 0.03 vs. 1.52 +/- 0.03, p < 0.0001) and the Zung Anxiety Scale (1.96 +/- 0.02 vs. 1.40 +/- 0.04, p < 0.0001). In addition, subjects in the INS group reported significantly greater impairments in specific QoL domains on the QoL inventory, and the Work and Daily Activities Inventory. No differences were observed between subjects in the INS group who were receiving treatment for insomnia versus those who were untreated. The results of this study indicate that significant QoL impairments are associated with insomnia.